BRAF inhibitors: resistance and the promise of combination treatments for melanoma

Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval of targeted pathway inhibitor drugs....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Griffin, Merope, Scotto, Daniele, Josephs, Debra H., Mele, Silvia, Crescioli, Silvia, Bax, Heather J., Pellizzari, Giulia, Wynne, Matthew D., Nakamura, Mano, Hoffmann, Ricarda M., Ilieva, Kristina M., Cheung, Anthony, Spicer, James F., Papa, Sophie, Lacy, Katie E., Karagiannis, Sophia N.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652848/
https://ncbi.nlm.nih.gov/pubmed/29100459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19836
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki